BrainStorm Cell Therapeutics Inc. (BCLI) revenue by segment

BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30

$0.77−0.01 (-1.17%)

Close on Oct 19, 2026Market cap $8.50MP/E –Yield –

BrainStorm Cell Therapeutics Inc. revenue by segment

BrainStorm Cell Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.

See a number that looks wrong?